A Randomized, Multicenter,Open-Label Study of YONDELIS, ET-743 (Ecteinascidin) Administered by Two Different Schedules (Weekly for 3 of 4 Weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment With an Anthracycline and Ifosfamide

Trial Profile

A Randomized, Multicenter,Open-Label Study of YONDELIS, ET-743 (Ecteinascidin) Administered by Two Different Schedules (Weekly for 3 of 4 Weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment With an Anthracycline and Ifosfamide

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Trabectedin (Primary) ; Dexamethasone
  • Indications Leiomyosarcoma; Liposarcoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 27 Jan 2011 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
    • 27 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Aug 2009 Results data available on line at http://jco.ascopubs.org.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top